{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:01:27Z","timestamp":1789912887822,"version":"4.0.1"},"reference-count":24,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Phlebology"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To examine the association between postoperative adjuvant venoactive drug (VAD) use and symptom relief and quality of life (QoL) in patients undergoing radiofrequency ablation (RFA) for symptomatic varicose veins of the great saphenous vein (GSV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective cohort study screened 565 consecutive patients who underwent RFA for symptomatic GSV varicose veins between June 2022 and June 2024. After application of the eligibility criteria, 500 patients were included and classified according to postoperative VAD use into a standard-care group (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 250) and a standard-care plus VAD group (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 250). Postoperative complication rates, Venous Clinical Severity Score (VCSS), Numeric Rating Scale (NRS), and Chronic Venous Insufficiency Questionnaire (CIVIQ) scores were compared.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The observation group had a significantly lower total complication rate (3.60% vs 12.80%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). VCSS scores at 1\u00a0week and 3\u00a0months and NRS scores at 1\u00a0day, 1\u00a0week, and 3\u00a0months were lower in the observation group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). CIVIQ scores were significantly higher in the observation group at 3 months and 1 year postoperatively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). Exploratory subgroup analyses showed generally consistent between-group patterns across the predefined age, disease-duration, and sex subgroups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adjunctive VAD therapy following GSV RFA was associated with fewer postoperative complications, lower VCSS and NRS scores, and higher CIVIQ scores. These findings support further prospective evaluation of VAD therapy as an adjunct to postoperative management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02683555261490787","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:22:27Z","timestamp":1789741347000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of adjunctive venoactive drug therapy on symptom relief and quality of life following radiofrequency ablation for symptomatic great saphenous vein incompetence"],"prefix":"10.1177","author":[{"given":"Mingyang","family":"Shen","sequence":"first","affiliation":[{"name":"Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University"},{"name":"The Affiliated Huaian No.1 People\u2019s Hospital of Nanjing Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maozhen","family":"Chen","sequence":"additional","affiliation":[{"name":"The Affiliated Huaian No.1 People\u2019s Hospital of Nanjing Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1296-2253","authenticated-orcid":false,"given":"Xiaoqiang","family":"Li","sequence":"additional","affiliation":[{"name":"Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2024.101842"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/02683555211060622"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2021.12.024"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2023.08.011"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/02683555221114537"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/17085381211058587"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2025.102258"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.23.00854"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1308\/rcsann.2020.0116"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2023.03.015"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.10961"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-0881-7"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/02683555231169088"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17010059"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24183316"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-9590.18.03975-5"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/07315724.2021.1909510"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/02683555211002331"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01216-w"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0731-z"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.3390\/nu13030999"},{"issue":"6","key":"e_1_3_6_23_2","first-page":"457","article-title":"Monocyte chemoattractant protein 1 plasma concentration in blood from varicose veins decreases under venoactive drug treatment","volume":"41","author":"Zolotukhin I","year":"2022","unstructured":"Zolotukhin I, Golovanova O, Efremova O, et al. Monocyte chemoattractant protein 1 plasma concentration in blood from varicose veins decreases under venoactive drug treatment. Int Angiol 2022; 41(6): 457\u2013463. https:\/\/doi.org\/10.23736\/S0392-9590.22.04940-9","journal-title":"Int Angiol"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.23.01264"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.33529\/ANGI02020201"}],"container-title":["Phlebology: The Journal of Venous Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02683555261490787","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02683555261490787","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02683555261490787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:19:58Z","timestamp":1789910398000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02683555261490787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":24,"alternative-id":["10.1177\/02683555261490787"],"URL":"https:\/\/doi.org\/10.1177\/02683555261490787","relation":{},"ISSN":["0268-3555","1758-1125"],"issn-type":[{"value":"0268-3555","type":"print"},{"value":"1758-1125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"02683555261490787"}}